Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Pharmaceuticals
- Disease
- Therapeutic
- Diagnostic
- Diagnostic Substances
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 6188
License Grant
The Licensor, a Canadian pharmaceutical company involved in the development and commercialization of high quality, polysaccharide-based therapeutic products used in the treatment of osteoarthritis and certain types of cystitis, entered into a royalty Agreement for sales of Uracyst® product, for the treatment of interstitial cystitis, (an inflammatory disease of the urinary bladder wall). The Licensee is undisclosed.
Field of Use
The rights granted apply to the healthcare industry.
IPSCIO Record ID: 612
License Grant
The University hereby grants to Canadian Licensee an exclusive, worldwide license under the Patent Rights to make, have made, use, sell, offer for sale, and import Licensed Products and to practice Licensed Methods and to use Technology, in the Field of disorders of the lower urinary tract, defined as the bladder, prostate and urethra, until the expiration of the patents or 10 years.
License Property
Whereas, the inventions disclosed in UCSD Case Docket Nos. SD2003-049 and SD2004-134 and titled Novel Intravesical Therapy For Immediate Symptom Relief And Chronic Therapy In Interstitial Cystitis Patients (Invention), were made in the course of research at UCSD by Dr. C. Lowell Parsons (hereinafter, the Inventor) and are covered by Patent Rights.
Patent Rights means any of the following the US patent application (60/540,186, titled Novel Interstitial Therapy For Immediate Symptom Relief And Chronic Therapy In Interstitial Cystitis) disclosing and claiming the Inventions, filed by Inventors and assigned to University.
Field of Use
Field means disorders of the lower urinary tract, defined as the bladder, prostate and urethra.
IPSCIO Record ID: 5917
License Grant
The Licensor entered into a License Agreement with the Licensee to grant the exclusive rights and License to use the methods and technical know-how for the purposes of manufacturing, marketing and selling Uracyst-S products in specified territories in Europe. In consideration, the Licensor is to receive a combination of non-recurring, non-refundable License fees and royalty payments. The License fees are due upon achievement of specified milestones.
License Property
Uracyst, a chondroitin sulfate-based therapy, and the Uracyst Test Kit were developed to identify defective bladder linings and provide symptomatic relief to the over 70,000 patients in Canada with interstitial cystitis. Each of these products has received regulatory approval in Canada. Uracyst and the Uracyst Test Kit are patented in the United States and in Canada with international patents pending.
IPSCIO Record ID: 29423
License Grant
Canadian Licensor hereby grants to Licensee the exclusive right and license, even as to Licensor, to any and all Methods and Technical Know-How, trade secrets, and proprietary information related to the Product in the Field in the Territory.
License Property
Whereas the Canadian Licensor has developed and owns methods and technical know-how relating to the manufacture and use of their proprietary product Uracyst®, a sterile sodium chondrotin sulfate solution 2.0% in a 20 mL vial, and the Uracyst® Test Kit containing 1 vial of Solution K (sterile potassium chloride solution 3.0% and 1 vial Uracyst® 2.0%. And whereas Licensor owns certain trade names, trademarks, logos, emblems and indicia of origin which are used in association with Uracyst®.
Uracyst® Test Kit is a patented technology for the diagnosis and treatment of interstitial cystitis (IC), an inflammatory disease of the urinary bladder wall.
And whereas Licensee is desirous of obtaining from Licensor the methods and technical know-how and the right and license to market, distribute and sell the Products (as such term is hereinafter defined) in the Territory (as such term is hereinafter defined), upon the terms and subject to the conditions hereinafter set forth. Methods and Technical Know-How and Grant of Licenses Subject to the provisions of this Agreement and for the Term hereinafter specified, Licensor hereby covenants and agrees to provide Licensee with the Methods and Technical Know-How necessary to enable Licensee to obtain regulatory approval for the Products in the Territory. All costs related to such regulatory approval applications shall be the obligation of Licensee. Methods and Technical Know-How materials, methods and other regulatory documents per Appendix 1 will be supplied at Licensor's cost. Subject to the provisions of this Agreement and for the Term hereinafter specified, Licensor hereby grants to Licensee the exclusive right and license, even as to Licensor, to develop, market, promote, offer to sell, sell, have sold, distribute, import, grant sublicenses, or otherwise dispose of Products in the Field in the Territory.
Licensed Technology Licensee, its consultants, and/or the FDA shall have rights of access to any and all information, including, but not limited to, trade secrets and Methods and Technical Know-How necessary to secure regulatory approvals. Trade Names and Trademarks Licensee shall have the right to sell the Products in the Territory under its own trade name and trademarks. Such trade names and trademarks, including any goodwill belonging to them, shall be the exclusive property of Licensee. Licensee shall have the right, but not the obligation, to use the trade name and/or trademark Uracyst® for use in the Territory. Licensor shall retain the Uracyst® trade name outside the Territory. Licensee may only grant sublicenses to third parties in order to import, market, promote, distribute and sell the Products in the Territory, provided that the licenses granted to such sub-licensees are not inconsistent with the licenses granted to Licensee.
Field of Use
Field means the treatment of all human conditions in the Territory.
IPSCIO Record ID: 4644
License Grant
Licensor hereby grants to Licensee and its Affiliates a nonexclusive license under the Licensed IP Rights to conduct research and to develop, make, have made, use, offer for sale, sell and import Products in the Territory for use in the Field. Licensee or its affiliates or sublicensee’s shall not sponsor or conduct any clinical work without the prior written approval of Licensor.
Such license is non-exclusive; provided that, between the six-month anniversary of the Effective Date and the 12-month anniversary of the Effective Date, the Licensee will have the right, at its option, to convert such non-exclusive license to an exclusive license for the remaining term of the Agreement, subject only to certain specified existing sublicenses.
License Property
“Inventions†shall mean, collectively, the inventions disclosed in UCSD Case Docket Nos. SD2003-049 and SD2004-134 and titled “Novel Intravesical Therapy For Immediate Symptom Relief And Chronic Therapy In Interstitial Cystitis Patientsâ€.
The rights are to commercially compound a patented combination of alkalized lidocaine and heparin compounded formulation, for the prevention or treatment of disorders of the lower urinary tract from the Licensor. Physicians in the US and abroad have been prescribing and instilling this compounded drug formulation in different dosages to treat individual patients suffering from interstitial cystitis, also known as painful bladder syndrome (IC/PBS). Compounded alkalized lidocaine and heparin instillation procedures have been reimbursable by private healthcare providers and to Medicare beneficiaries under CPT Code 51700. The patented formulation first became available in 2011 as a compounded drug.
Field of Use
“Field of Use†shall mean the prevention or treatment of disorders of the lower urinary tract, defined as the bladder, prostate, urethra, and related conditions.
IPSCIO Record ID: 1167
License Grant
The Licensee has Licensed the URG101 technology, a bladder instillation for Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC), from the University. The License Agreement is exclusive with regard to patent rights and non-exclusive with regard to the written technical information. The Licensee may also grant a subLicense to third parties.
Field of Use
The rights granted apply to the medical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
